Showing 1 - 3 results of 3 for search 'Shiangtung W. Jung', query time: 0.02s Refine Results
  1. 1
    Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD

    Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRD by Michael Walsh, Claudette Bethune, Andrew Smyth, Jessica Tyrwhitt, Shiangtung W. Jung, Rosie Z. Yu, Yanfeng Wang, Richard S. Geary, Jeffrey Weitz, Sanjay Bhanot

    Published 2022-02-01
    Get full text
    Article
  2. 2
    PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients

    PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients by Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot

    Published 2021-08-01
    Get full text
    Article
  3. 3
    Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data

    Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data by Nicholas J. Viney, Shuling Guo, Li‐Jung Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien Burel, Sue Murray, Gustavo Buchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia

    Published 2021-02-01
    Get full text
    Article

Search Tools: